Despite no indication ofsusceptability, I'm more afraid of stroke than fracture.
"In the ARCH trial, the absolute risk of having a major cardiovascular event in the first year of treatment was 1.1% in the alendronate arm and 2.0% in the romosozumab group, whereas new clinical fractures occurred in 5.4% of the patients treated with alendronate and 3.9% of those treated with romosozumab."
https://www.tandfonline.com/doi/full/10.1080/14740338.2023.2173737#:~:text=In%20the%20ARCH%20trial%2C%20the,of%20those%20treated%20with%20romosozumab
2.0% is very low risk.
Wishing you the best